Bateman AR - Search Results

1

Viral fusogenic membrane glycoproteins kill solid tumor cells by nonapoptotic mechanisms that promote cross presentation of tumor antigens by dendritic cells.

Bateman AR, Harrington KJ, Kottke T, Ahmed A, Melcher AA, Gough MJ, Linardakis E, Riddle D, Dietz A, Lohse CM, Strome S, Peterson T, Simari R, Vile RG. Bateman AR, et al. Cancer Res. 2002 Nov 15;62(22):6566-78. Cancer Res. 2002. PMID: 12438252

2

Enhancing the efficacy of a weak allogeneic melanoma vaccine by viral fusogenic membrane glycoprotein-mediated tumor cell-tumor cell fusion.

Linardakis E, Bateman A, Phan V, Ahmed A, Gough M, Olivier K, Kennedy R, Errington F, Harrington KJ, Melcher A, Vile R. Linardakis E, et al. Cancer Res. 2002 Oct 1;62(19):5495-504. Cancer Res. 2002. PMID: 12359759

3

A new genetic method to generate and isolate small, short-lived but highly potent dendritic cell-tumor cell hybrid vaccines.

Phan V, Errington F, Cheong SC, Kottke T, Gough M, Altmann S, Brandenburger A, Emery S, Strome S, Bateman A, Bonnotte B, Melcher A, Vile R. Phan V, et al. Nat Med. 2003 Sep;9(9):1215-9. doi: 10.1038/nm923. Epub 2003 Aug 17. Nat Med. 2003. PMID: 12925849

4

Allogeneic tumor cells expressing fusogenic membrane glycoproteins as a platform for clinical cancer immunotherapy.

Errington F, Bateman A, Kottke T, Thompson J, Harrington K, Merrick A, Hatfield P, Selby P, Vile R, Melcher A. Errington F, et al. Clin Cancer Res. 2006 Feb 15;12(4):1333-41. doi: 10.1158/1078-0432.CCR-05-1113. Clin Cancer Res. 2006. PMID: 16489091 Free article.

5

Adoptive transfer of immature dendritic cells with autologous or allogeneic tumor cells generates systemic antitumor immunity.

Melcher A, Todryk S, Bateman A, Chong H, Lemoine NR, Vile RG. Melcher A, et al. Cancer Res. 1999 Jun 15;59(12):2802-5. Cancer Res. 1999. PMID: 10383135

6

Fusogenic membrane glycoproteins as a novel class of genes for the local and immune-mediated control of tumor growth.

Bateman A, Bullough F, Murphy S, Emiliusen L, Lavillette D, Cosset FL, Cattaneo R, Russell SJ, Vile RG. Bateman A, et al. Cancer Res. 2000 Mar 15;60(6):1492-7. Cancer Res. 2000. PMID: 10749110

7

Viral fusogenic membrane glycoprotein expression causes syncytia formation with bioenergetic cell death: implications for gene therapy.

Higuchi H, Bronk SF, Bateman A, Harrington K, Vile RG, Gores GJ. Higuchi H, et al. Cancer Res. 2000 Nov 15;60(22):6396-402. Cancer Res. 2000. PMID: 11103804

8

Intratumoral expression of a fusogenic membrane glycoprotein enhances the efficacy of replicating adenovirus therapy.

Ahmed A, Jevremovic D, Suzuki K, Kottke T, Thompson J, Emery S, Harrington K, Bateman A, Vile R. Ahmed A, et al. Gene Ther. 2003 Sep;10(19):1663-71. doi: 10.1038/sj.gt.3302064. Gene Ther. 2003. PMID: 12923565

9

Dendritic cells for the immunotherapy of cancer.

Melcher A, Bateman A, Harrington K, Ahmed A, Gough M, Vile R. Melcher A, et al. Clin Oncol (R Coll Radiol). 2002 Jun;14(3):185-92. doi: 10.1053/clon.2001.0038. Clin Oncol (R Coll Radiol). 2002. PMID: 12109820 Review. No abstract available.

10

Lack of specificity of cell-surface protease targeting of a cytotoxic hyperfusogenic gibbon ape leukaemia virus envelope glycoprotein.

Kirkham LA, Bateman AR, Melcher AA, Vile RG, Fielding AK. Kirkham LA, et al. Among authors: bateman ar. J Gene Med. 2002 Nov-Dec;4(6):592-600. doi: 10.1002/jgm.306. J Gene Med. 2002. PMID: 12439851

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

70 results

Search Page

Filters